Skip to search formSkip to main contentSkip to account menu

BAL9141

Known as: BAL 9141 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
New therapeutic alternatives have been developed in the last years for the treatment of multidrug- resistant Gram-positive… 
Highly Cited
2005
Highly Cited
2005
ABSTRACT Ceftobiprole (formerly BAL9141), the active component of the prodrug BAL5788 (ceftobiprole medocaril), is a novel… 
Highly Cited
2004
Highly Cited
2004
ABSTRACT BAL9141, a new antimicrobial agent belonging to the class of parenteral pyrrolidinone-3-ylidenemethyl cephalosporins, is… 
Highly Cited
2004
Highly Cited
2004
ABSTRACT BAL5788 is a water-soluble prodrug of BAL9141, a new broad-spectrum cephalosporin with high levels of in vitro activity… 
Highly Cited
2004
Highly Cited
2004
ABSTRACT BAL5788 is the water-soluble prodrug of BAL9141, a novel broad-spectrum cephalosporin with potent bactericidal… 
Highly Cited
2003
Highly Cited
2003
BAL9141 has been reported to have inhibitory activity against methicillin-resistant Staphylococcus aureus (MRSA), many… 
Highly Cited
2002
Highly Cited
2002
Community-acquired and nosocomial infections caused by multidrug-resistant Gram-positive pathogens continue to increase in… 
Highly Cited
2002
Highly Cited
2002
ABSTRACT The therapeutic efficacy of BAL9141 (formerly Ro 63-9141), a novel cephalosporin with broad in vitro activity that also… 
2002
2002
ABSTRACT The activities of BAL9141 (formerly Ro 63-9141), a novel pyrrolidinone-3-ylidenemethyl cephalosporin, against 244…